Evidence map›Paper›PMID 34335849›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Gualou Guizhi Granule Suppresses LPS-Induced Inflammatory Response of Microglia and Protects against Microglia-Mediated Neurotoxicity in HT-22 via Akt/NF-

Xiaona Chang, Yaling Fang, Yuqin Zhang, Yaojun Liu, Liming Fan, Lihong Nan, Wei Xu, Yu Lin, Kedan Chu, Guohong Yan

Abstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaona ChangPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.
Yaling FangPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.
Yuqin ZhangPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.ORCID https://orcid.org/0000-0002-1449-6209
Yaojun LiuPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.
Liming FanPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.
Lihong NanPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.
Wei XuPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.
Yu LinPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.ORCID https://orcid.org/0000-0001-5033-3733
Kedan ChuPharmacy College of Fujian University of Traditional Chinese Medicine, Shangjie Minhou, Fuzhou, Fujian, China.
Guohong YanPeople's Hospital Affiliated of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.ORCID https://orcid.org/0000-0002-1978-9393

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroinflammation plays a crucial part in the commencement and advancement of ischemic stroke. Gualou Guizhi granule (GLGZG) is known to well exhibit neuroprotective effect, but it is not known whether GLGZG can regulate the inflammatory process at the cellular level in BV2 microglia cells and protect against microglia-mediated neurotoxicity in neurons. Herein, we aimed to investigate the anti-inflammatory effects of GLGZG on BV2 microglia cells and protection against microglia-mediated neurotoxicity in neurons.

Identifiers

PMID34335849
PMCPMC8321734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.